The progressed atrioventricular block associated with ticagrelor therapy may not require permanent pacemaker after acute coronary syndrome; it may be reversible.

[1]  J. Tu,et al.  Ticagrelor and bradycardia: a nested case–control study , 2015, Pharmacoepidemiology and drug safety.

[2]  R. Choussat,et al.  Side effects of ticagrelor: Sinus node dysfunction with ventricular pause. , 2015, International journal of cardiology.

[3]  S. Manzano-Fernández,et al.  Ticagrelor related dyspnea in patients with acute coronary syndromes: Incidence and implication on ticagrelor withdrawn. , 2015, International journal of cardiology.

[4]  M. Keltai,et al.  Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2015, Journal of the American Heart Association.

[5]  M. Halabi,et al.  Life-threatening complete atrioventricular block associated with ticagrelor therapy. , 2015, International journal of cardiology.

[6]  R. Teng,et al.  Safety, tolerability, pharmacokinetics and pharmacodynamics of high single-ascending doses of ticagrelor in healthy volunteers. , 2013, International journal of clinical pharmacology and therapeutics.

[7]  P. Pais,et al.  The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. , 2011, Journal of the American College of Cardiology.

[8]  J. Aronson.  Safety , 2009, BMJ : British Medical Journal.

[9]  A. Yıldırım,et al.  Atrioventricular block associated with ticagrelor therapy may require permanent pacemaker. , 2016, International journal of cardiology.